Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review - 15/07/23
Doi : 10.1016/j.jaad.2023.03.036
Christine Learned, BA a, Stephanie R. Cohen, MD a, Kaitlynne Cunningham, BS a, Sarah Alsukait, MBBS a, Sueheidi Santiago, MD b, Jun Lu, MD b, Marti Rothe, MD b, Anna Nichols, MD c, David Rosmarin, MD d, ⁎ 
a Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
b Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut
c Department of Dermatology, Univeristy of Miami Health Systems, Miami, Florida
d Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana
∗Correspondence to: David Rosmarin, MD, Department of Dermatology, Indiana University School of Medicine, 545 Barnhill Dr, Indianapolis, IN 46202Department of DermatologyIndiana University School of Medicine545 Barnhill DrIndianapolisIN46202
Key words : blistering disorders, bullous pemphigoid, dermatology, dupilumab, dupixent, immunobiologic
| Funding sources: None. |
|
| IRB approval status: Approved by Tufts Institutional Review Board, approval number 1249. |
|
| Reprints not available from the authors. |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 2
P. 378-382 - août 2023 Retour au numéro
Article précédent
- Prurigo pigmentosa: A multi-institutional retrospective study
- Amy Shen, Carol E. Cheng, Rhea Malik, Erica Mark, Natalia Vecerek, Nolan Maloney, Joan Leavens, Vinod E. Nambudiri, Art P. Saavedra, Marcia Hogeling, Scott Worswick
- Epidemiology of tinea capitis causative species: An analysis of fungal culture results from a major United States national commercial laboratory
- Jeremy A.W. Gold, Kaitlin Benedict, Shawn R. Lockhart, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?